Legal-Graphics' 5-17-21 COVID Timeline
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
23 April 2020 Update
20 April – 23 April 2020 Contents I. Summary .............................................................................................................................1 II. European Union .................................................................................................................5 III. France ...............................................................................................................................6 IV. Italy ...................................................................................................................................7 V. Germany ............................................................................................................................8 VI. Spain ...............................................................................................................................10 VII. United Kingdom .............................................................................................................10 I. SUMMARY Number of cases: 1,009,762 (including the UK) Number of deaths: 108,223 • The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a meeting on 15 April to discuss the progress of the measures regarding availability of medicines for European patients during the COVID-19 pandemic. They also updated the Q&A document on regulatory expectations for medicinal products for human use during the COVID-19 pandemic on 20 April. On 21 April, they set-up the fast-track system to support essential medicines for COVID-19 treatment, -
Written Evidence from Spotlight on Corruption1 (PGG18) the Public
Written evidence from Spotlight on Corruption1 (PGG18) The Public Administration and Constitutional Affairs Committee Propriety of governance in light of Greensill inquiry Introduction The revelations arising from the Greensill affair and its fallout, coming alongside other recent and ongoing scandals, have exposed significant weaknesses in the UK system for managing conflicts of interest, lobbying, and business appointments. This is a vital opportunity to bring the UK’s standards landscape up to date, and to ensure that integrity and ethics in government are regulated in a way that befits a modern democracy. Taking action to strengthen the UK’s integrity and ethics framework would benefit the UK by helping to: build trust in politicians and government; strengthen the stability, predictability and attractiveness of the UK as a place to do business; give the UK greater credibility on the international stage in promoting democracy and good governance; and implement outstanding recommendations made by international bodies such as the UN and Council of Europe about how the UK can improve its integrity and ethics framework to prevent and tackle corruption. Key Recommendations 1. Integrity and Ethics legislation. The government should consult on the introduction of an Integrity and Ethics Bill, by the spring of 2022, which gives legislative effect to: the Law Commission’s recommendations on the introduction of a corruption in public office offence; recommendations made by international bodies to put ACOBA and the Independent Advisor on Ministerial Interests on a statutory footing; recommendations that are likely to be made by the Committee on Standards in Public Life’s Standards Matters 2.0 review in the Autumn of 2021; and recommendations likely to be made from both the Boardman review and parliamentary committees such as PACAC, including legislative reform to the Lobbying Act. -
UK COVID-19 Vaccines Delivery Plan
UK COVID-19 vaccines delivery plan Published 11 January 2021 Contents 1. Ministerial foreword ....................................................................................................... 3 2. Executive summary and scope ..................................................................................... 4 Supply .............................................................................................................................. 5 Prioritisation ...................................................................................................................... 6 Places ............................................................................................................................... 7 People .............................................................................................................................. 8 Tracking our progress ....................................................................................................... 9 3. Supply ......................................................................................................................... 10 Developing new vaccines ............................................................................................... 10 Ensuring vaccines meet strict safety standards for deployment ..................................... 17 Building UK manufacturing capability ............................................................................. 21 4. Prioritisation ............................................................................................................... -
Legal-Graphics' 2-19-21 COVID Timeline
Number of days Overview: Year 2 of COVID since first sign of virus Nov. 23, 2020 Dec. 3, 2020 Dec. 11, 2020 Dec. 21, 2020 Dec. 30, 2020 Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Link to Source over 1,400,000 over 1,500,000 over 1,600,000 over 1,700,000 over 1,800,000 Signs of Virus 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 Key Events Nov. 16, 2020 Nov. 18, 2020 Nov. 21, 2020 Nov. 25, 2020 Nov. 27, 2020 Nov. 30, 2020 Dec. 3, 2020 Dec. 6, 2020 Dec. 8, 2020 Dec. 11, 2020 Dec. 14, 2020 Dec. 17, 2020 Dec. 21, 2020 Dec. 22, 2020 Dec. 26, 2020 Dec. 29, 2020 Dec. 31, 2020 Jan. 3, 2021 Good News! Moderna says data FDA allows US cases top Picture of US Demand for live Moderna to request Map showing US UK gears up for Chart of cumulative Pfizer vaccine to be How do the Pfizer Vaccinations reach How the Pfizer Vaccines across Could AZD7442 Map showing How vaccinations Interactive US Map shows its vaccine 1st rapid virus test 12 million ... spread economy is Christmas trees emergency states with the huge vaccination number of deaths OK’d in days - and Moderna US nursing homes and Moderna the world prevent COVID-19 which countries were developed by county showing Legal Matters is more than that gives results 'faster' and 'broader' worrisome skyrockets amid authorization their highest number plan watched by country (by “normal” next fall vaccines work? vaccines compare infection have rolled out so quickly risk for COVID 94% effective at home than ever as virus toll of virus coronavirus vaccine of virus deaths by the world number of days in those exposed? a COVID-19 vaccine inflicts damage since 100 deaths Dec. -
Emerging Leaders in Biosecurity Initiative
Emerging Leaders in Biosecurity Initiative Class of 2017 A competitive fellowship program created to identify, develop, and provide networking opportunities Yearbook for the next generation of leaders in biosecurity. Emerging Leaders in Biosecurity Initiative Contents Letter: 3 Thomas V. Inglesby, Director; Anita Cicero, Deputy Director, Johns Hopkins Center for Health Security Executive Steering Committee 5 Class of 2017 Fellows 9-35 ELBI 2017 Year in Review 36-37 ELBI Program Staff 41 ELBI Alumni 42 Cover and Inside Cover Photo Overlay: Swine Flu Strain Virus Particles. Col- orized transmission electron micrograph of negatively stained SW31 (swine strain) influenza virus particles. Credit: NIAID Emerging Leaders in Biosecurity Initiative The ELBI Fellowship program is made possible through financial support from the Open Philanthropy Project, under management by the Johns Hopkins Center for Health Security, and with the leadership of the ELBI Executive Steering Committee. For more information, please visit the ELBI website: http://www.centerforhealthsecurity.org/our-work/emergingbioleaders Center for Health Security “Modern conditions make the scenario of a global pandemic more likely. Humans are encroaching on animal environments, raising chances for pathogens to adapt from animals to people. An increasing share of the planet lives in megacities, heightening the likelihood of person-to-person transmission of pathogens. The movement of people and microbes around the globe is more efficient than ever. The recent outbreaks of SARS, MERS, and Ebola are only small glimpses of how quickly a deadly virus can spread.” Tom Inglesby and Benjamin Haas Foreign Affairs November 21, 2017 Middle East Respiratory Syndrome Coronavirus particle envelope proteins immunolabeled with Rabbit HCoV-EMC/2012 primary antibody and Goat an- 1 ti-Rabbit 10 nm gold particles. -
SYRA MADAD, D.H.Sc, M.Sc., MCP
SYRA MADAD, D.H.Sc, M.Sc., MCP Syra Madad, D.H.Sc., M.Sc., MCP is nationally recognized leader in public health and special pathogen preparedness and response. She is Senior Director, System-wide Special Pathogens Program at New York City Health + Hospitals, the nation’s largest municipal healthcare delivery system overseeing special pathogen preparedness and response efforts across 11 acute care hospitals in addition to post-acute/long-term care facilities and ambulatory care sites. She is Principal Investigator of NYC Health + Hospitals Center for Global Healthcare Preparedness to Special Pathogens. In addition, Dr. Madad is Core Faculty in the National Ebola Training and Education Center (NETEC), funded by the Centers for Disease Control and Prevention (CDC) and the Assistant Secretary for Preparedness and Response (ASPR) and Assistant Professor in the Graduate Biotechnology/Biodefense Program at the University of Maryland. She is an Alumni Fellow at Johns Hopkins Bloomberg School of Public Health, Center for Health Security’s Emerging Leaders in Biosecurity Program and the Federal Bureau of Investigation’s Behavioral Informatics & Technological Enterprise Studies Program. Dr. Madad earned her Doctoral degree in Health Science with a concentration in Global Health from Nova Southeastern University, graduating with Alpha Eta Health Science Honor Society status. She obtained her Master of Science degree in Biotechnology with a concentration in Biodefense and Biosecurity and Bachelor of Science degree in Psychology from the University of Maryland. Dr. Madad holds numerous professional certifications, licenses and training certificates including Master Continuity Practitioner Certification (FEMA), Advanced Emergency Planning Certification, All Hazard Response (CBRNE) Training for Laboratory Personnel, Biosafety Level III Training, and Identification of the Primary Select Agents of Bioterrorism Training. -
La Verdad De La Pandemia Os Gusta Y Seguís Siendo Mis Mecenas, Pronto Nos Pondremos a Trabajar En El Siguiente Libro
Índice Portada Sinopsis Dedicatoria Cita INTRODUCCIÓN. EL PRINCIPIO DEL CAOS PRIMERA PARTE. HECHOS 1. «TODO ESTÁ BAJO CONTROL» The Economist dixit Wuhan: un suceso local de alcance global El banco de virus más grande de Asia Cifras y muertes que no cuadran… La «orden»: confinamiento de la población El confinamiento de Wuhan… … Y China tiene el control El papel de la OMS Un espejo para comprender: Taiwán 2. HISTORIA DE UNA INFAMIA La OMS se alinea con el poder El «profeta»Tedros Adhanom La ideología del poder: el «Informe Kissinger» y los globócratas Nos matan con vacunas: la infertilidad de las mujeres Gursaran Pran Talwar y la vacuna anticonceptiva Bill Gates, vacunas y demografía La pandemia de Bill Gates La vacuna de Gates para el coronavirus SEGUNDA PARTE. LA IDEOLOGÍA DE LA ÉLITE 3. LABORATORIOS DE MANIPULACIÓN SOCIAL La Escuela de Chicago Mass Communication Research La Escuela de Fráncfort Tavistock Institute Estudios Culturales Método crítico versus colaboración con la superélite El MIT: el laboratorio actual Alex Pentland, el gurú de la élite globalista El MIT como faro de la élite Los amos del mundo iniciaron el camino: el Club Bilderberg 4. MEDIOS DE COMUNICACIÓN Y MENTIRAS Poder y comunicación: algunos apuntes históricos La Antigüedad La Edad Media La Edad Moderna La Edad Contemporánea Comunicación y cultura de masas Manipulación y propaganda El poder del cine La globalización: ¿quién tiene el poder? La «sociedad red» La comunicación en la «sociedad red» Normópatas El poder mediático y sus tentáculos La ideología de los medios de comunicación y la creación de alianzas Alphabet (Google), Amazon, Facebook, Apple, Microsoft y Netflix La sociedad domesticada con el mensaje único Los grandes conglomerados mediáticos y el Club Bilderberg Jeff Bezos, The Washington Post y Amazon Eric Schmidt, YouTube y Google Facebook, mucho más que una red social Mark Zuckerberg y Bilderberg: los dueños de Facebook Los jueces TERCERA PARTE. -
COVID-19 Interim Vaccination Plan V.5 Pennsylvania
COVID-19 Interim Vaccination Plan V.5 Pennsylvania PA COVID-19 Vaccine Task Force/PA Department of Health JANUARY 19, 2021 |VERSION 5.0 PENNSYLVANIA COVID-19 INTERIM VACCINATION PLAN Table of Contents Introduction……………………………………………………………………………………………………………………………………….2 Section 1: COVID-19 Vaccination Preparedness Planning ......................................................................... 3 Section 2: COVID-19 Organizational Structure and Partner Involvement ................................................. 4 Section 3: Phased Approach to COVID-19 Vaccination ........................................................................... 11 Section 4: Critical Populations ................................................................................................................. 17 Section 5: COVID-19 Provider Recruitment and Enrollment ................................................................... 21 Section 6: COVID-19 Vaccine Administration Capacity ........................................................................... 25 1. Health and Medical Infrastructure .......................................................................................... 25 2. Occupational Health Clinics and Closed Points of Dispensing (PODs) ..................................... 26 3. Expanded Outreach to Ensure Vaccine Access ........................................................................ 27 4. Staffing .................................................................................................................................... -
Role and Responsibilities of the Chair of the Vaccine Taskforce
Chair of the Vaccine Taskforce Information pack for applicants Closing date: Midday on Friday 14 May 2021 Reference no: VAC-1775 Follow us on Twitter @appointmentsdh Table of Contents Section 1: Role, responsibilities and person specification.................................................... 2 Section 2: How to apply ....................................................................................................... 4 2.1 Making an application ............................................................................................. 4 2.2 The selection process ............................................................................................. 7 2.3 Eligibility criteria ...................................................................................................... 9 2.4 How we will manage your personal information .................................................... 10 Chair of the Vaccine Taskforce - Information pack for applicants Section 1: Role and responsibilities of the Chair of the Vaccine Taskforce The Chair must enable the Vaccine Taskforce to achieve their three core objectives during the pandemic period: a. To secure access to promising vaccine/s for the UK population. b. To make provision for international distribution of vaccines. c. To strengthen the UK’s onshore capacity and capability in vaccine development, manufacturing, and supply chain to provide resilience for this and future pandemics. In recognising that the Taskforce has now been in existence for over a year, delivering these objectives -
Clinical Laboratory Preparedness and Response Guide
TABLE OF CONTENTS Table of Contents ...................................................................................................................................................................................... 2 State Information ....................................................................................................................................................................................... 7 Introduction .............................................................................................................................................................................................. 10 Laboratory Response Network (LRN) .......................................................................................................................................... 15 Other Emergency Preparedness Response Information: .................................................................................................... 19 Radiological Threats ......................................................................................................................................................................... 21 Food Safety Threats .......................................................................................................................................................................... 25 BioWatch Program ............................................................................................................................................................................ 27 Bio Detection Systems -
Edical Sciences Esearch (IJAMSCR)
Dr. N. Sriram et al / Int. J. of Allied Med. Sci. and C lin. Research Vol-9(1) 2021 [ 1-10] International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR) ISSN: 2347 -6567 IJAMSCR |Volume 9 | Issue 1 | Jan - Mar - 2021 www.ijamscr.com Review article Medical research Development of new covid -19 vaccines from india : A systematic review 1Dr. N. Sriram, 2S. Kameshwaran , 3Asokkumar DS , 4N. Elavarasan, 5M. Sarbudeen 1Department of Pharmaceutics, Hits College of Pharmacy, Bogaram, Ghatkesar, Hyderabad, Telangana, India 2-5 Excel college of Pharmacy, Komarapalayam, Namakkal, Tamilnadu – 637303. *Corresponding Author :Dr. N. Sriram email: [email protected] ABSTRACT Extreme acute respiratory syndrome Coronavirus 2 (SARS -CoV-2) is an extremely pathogenic new virus that has triggered the current worldwide coronavirus disease pandemic (COVID -19). Currently, substantial effort has been made to produce successful and safe medicines and SARS-CoV-2 vaccines. To avoid more morbidity and death, a successful vaccine is important. Though some regions which deploy COVID -19 vaccines on the basis of protection and immunogenicity data alone, the aim of vaccine research is to obtain d irect proof of vaccine effectiveness in protecting humans against SARS-CoV -2 and COVID-19 infections in order to selectively increase the production of effective vaccines. A SARS-CoV-2 candidate vaccine can function against infection, illness, or transmiss ion and a vaccine that is capable of minimising all of these components may lead to disease control. In this study, we discussed the Bharat Biotech and Covishield Serum Institute of India's Covaxin - India's First Indigenous Covid -19 Vaccine. -
'Astrazeneca' Covid-19 Vaccine
Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices.